Abstract Antibody–drug conjugates (ADCs) and immune-checkpoint inhibitors (ICIs) are reshaping breast cancer treatment, but the extent to which individual ADCs induce immunogenic cell death (ICD) remains construct specific.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Linghui
Contact Linghui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack